linjc16/ctgov huggingface dataset:
Retrospective Follow-up Study After Periacetabular Osteotomy in Adults

Study Overview
=================
Brief Summary
-----------------
This is a retrospective study assessing pre- and postoperative radiographic indices of hip dysplasia in order to identify factors predicting failure following Periacetabular Osteotomy (PAO).

Detailed Description
-----------------
Even though the PAO is applied worldwide and is the preferred joint preserving treatment some issues remains unclear and controversial. One is the exact indication for surgery and risk factors for early failure of the procedure. The is a retrospective cohort study assessing pre- and postoperative radiographic indices of hip dysplasia in order to identify factors predicting failure following PAO. The minimum duration of follow-up is 2 years. Failure following PAO is defined by a WOMAC pain score > 10 or the insertion of a total hip arthroplasty.

Official Title
-----------------
Retrospective Follow-up Study After Periacetabular Osteotomy in Adults

Conditions
-----------------
Congenital Deformity of Hip Joints

Intervention / Treatment
-----------------
* Procedure: Follow-up


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: PAO from 1999-2007
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| developmental dysplasia of the hip, PAO<br>All patients who underwent periacetabular osteotomy from 1999-2007 at the University Hospital of Aarhus | Procedure: Follow-up<br>* Follow-up<br>* Other names: WOMAC;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
BIO|CONCEPT.BIOMONITOR III

Study Overview
=================
Brief Summary
-----------------
The objective of the study is to confirm the safety and efficacy of the BIOMONITOR III system. Furthermore, the insertion procedure, the use and handling of the incision and insertion tools and the sensing quality of the BIOMONITOR III will be assessed.

Official Title
-----------------
BIO|CONCEPT.BIOMONITOR III

Conditions
-----------------
Atrial Fibrillation, Syncope, Tachyarrhythmia

Intervention / Treatment
-----------------
* Device: BIOMONITOR III


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient is at high risk of developing a clinically important cardiac arrhythmia; or Patient is undergoing investigation for symptoms such as palpitations, pre-syncope or syncope, that are suggestive of an underlying cardiac arrhythmia; or Patient is undergoing investigation for the detection of atrial fibrillation following cryptogenic stroke; or Patient is planned for AF ablative procedure or has already undergone an AF ablative procedure. Patient is able to understand the nature of study and has provided written informed consent. Patient is willing and able to perform all follow up visits at the study site. Patient is willing and able to use the CardioMessenger and accepts the BIOTRONIK Home Monitoring concept. Exclusion Criteria: Patients implanted with ICD or pacemaker. Patient is pregnant or breast feeding. Patient is less than 18 years old. Patient is participating in another interventional clinical investigation Patient´s life-expectancy is less than 6 months.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BIOMONITOR III<br> | Device: BIOMONITOR III<br>* Patients with ICM indication receive a third-generation implantable cardiac monitor<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adverse Events | (procedure / device related) | 1 month | 
| R-wave amplitude |  | 1 month | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Insertion procedure of the BIOMONITOR III by using the incision and insertion tools | Assessment of insertion procedure by using a questionaire about handling and time record. | At the day of insertion of the BIOMONITOR III | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Implantable Cardiac Monitor
The Effect of Chinese Herbal Formula (KSY) on HCV Carrier With Abnormal Liver Function

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to examine whether the Chinese herbal formula (KSY) is effective on HCV Carrier With Abnormal Liver Function.

Detailed Description
-----------------
percentage of change on HCV RNA titer and liver function (GPT).

Official Title
-----------------
An Evaluation of the Extract of KUAN SIN YIN on Hepatitis C: a Randomized, Double-blinded and Placebo-controlled Clinical Trial.

Conditions
-----------------
Liver Function

Intervention / Treatment
-----------------
* Drug: KSY


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 40 < GPT <200 HCV carrier Age: 18-65 yrs old Exclusion Criteria: Creatinine >2.0 mg/dL Total bilirubin > 2.0mg/dL Not suitable patients diagnosis by physician in charge.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: KSY diluted<br>KSY diluted, 100mg decoction by mouth per day for 6 weeks | |
| Experimental: KSY<br>KSY, 100mg decoction by mouth per day for 6 weeks | Drug: KSY<br>* Chinese herbal formula<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HCV RNA titer |  | 6 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum GPT level |  | 6 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
HCV carrier, Chinese herbal medicine, Liver function, HCV RNA titer
Ziprasidone vs Standard Therapy for Agitated Patients in the ED

Study Overview
=================
Brief Summary
-----------------
The primary objective is to determine if ziprasidone is superior to standard therapies in the emergency department treatment of the acutely agitated patient. The primary outcome will be the length of time taken until the patient is ready to be evaluated by the psychiatric service, or until a disposition is made.

Official Title
-----------------
Prospective Double Blind Randomized Trial of Intramuscular Ziprasidone Compared With Standard Antipsychotic Therapy For The Treatment Of The Acutely Agitated Patient In The Emergency Department

Conditions
-----------------
Psychosis, Agitation, Delirium

Intervention / Treatment
-----------------
* Drug: ziprasidone
* Drug: Standard therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Acutely agitated Requires chemical sedation Exclusion Criteria: Physician preference for a specific chemical sedative Known allergy to any study medications

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: ziprasidone<br> | Drug: ziprasidone<br>* ziprasidone 20mg IM<br>|
| Active Comparator: Standard therapy<br> | Drug: Standard therapy<br>* Haldol 5mg/ Ativan 2mg IM<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| length of time from triage until patient is either ready to be seen by psychiatry or is ready to have a disposition made |  | During ED stay | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Length of time taken to sedate patient |  | Ed visit | 
| Total time spent in restraints |  | ED visit | 
| Cost effectiveness of the therapy |  | ED visit | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Psychosis, Agitation, Delirium
Iron Deficiency Anemia in Twin Pregnancies

Study Overview
=================
Brief Summary
-----------------
All pregnant women with twin pregnancies were given oral iron according to the current recommended dose. Blood routine and ferritin were monitored during pregnancy to understand the therapeutic effect of oral iron on iron deficiency anemia and iron deficiency in pregnant women with twin pregnancies

Detailed Description
-----------------
All pregnant women with twin pregnancies were given oral iron according to the current recommended dose. Blood routine and ferritin were monitored every 2-4 weeks during pregnancy to understand the therapeutic effect of oral iron on iron deficiency anemia and iron deficiency in pregnant women with twin pregnancies.After delivery, we will test the neonatal ferritin and hemoglobin status. Our aim was to investigate the effects of iron supplementation during twin pregnancy on maternal and neonatal ferritin and anemia.

Official Title
-----------------
Prospective Study of Iron Deficiency Anemia in Twin Pregnancy

Conditions
-----------------
Anemia, Iron-Deficiency

Intervention / Treatment
-----------------
* Drug: Iron


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Chinese Pregnant women with twin pregnancies Exclusion Criteria: Single pregnancy Types of anemia other than iron deficiency anemia

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Anemia Correction Group<br>Continue to take the current medication orally at the current dose | Drug: Iron<br>* One of each type of iron was taken orally according to the instructions and followed every two weeks<br>* Other names: Chinese medicine filling iron agent;|
| Experimental: Anemia uncorrected group<br>Continue to take the current medication orally at the current dose | Drug: Iron<br>* One of each type of iron was taken orally according to the instructions and followed every two weeks<br>* Other names: Chinese medicine filling iron agent;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Routine blood | Routine blood and serum ferritin（ng/ml）were checked 2-4 weeks | 2-4 weeks after antenatal care | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum ferritin | routine blood and serum ferritin（ng/ml）were checked 2-4 weeks | 2-4 weeks after antenatal care |
Adjustment Exploratory Protocols and Functional Evaluation of New Non Invasive Devices in Patient Volunteers

Study Overview
=================
Brief Summary
-----------------
Parameters, sequences or paradigms optimisation in view of data quality and relevancy improvement.

Detailed Description
-----------------
Various tests are needed for methodological optimization of the several devices (per-operative MRI, MEG, EEG, SPECT-CT, motor platform) of the technological platform.

Official Title
-----------------
Adjustment Exploratory Protocols (MagnetoEncephaloGraphy Study : MEG, ElectroEncephaloGram : EEG, Magnetic Resonance Imaging : MRI, Functional MRI : MRIf, Motor Platform) and Functional Evaluation of New Non Invasive Devices (REX BIONICS Exoskeleton) in Patient Volunteers

Conditions
-----------------
Neurological Diseases

Intervention / Treatment
-----------------
* Device: Imaging devices


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Volunteers patient Male or female aged over 18 years Registered in the French social security scheme Signed informed consent Exclusion Criteria: Contraindication to Magnetoencephalography (MEG) and/or Electroencephalography (EEG) Contraindication to Magnetic resonance imaging (MRI) All categories of protected persons

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Patients<br>Imaging devices | Device: Imaging devices<br>* technological adjustment tests<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Magnetic brain activity | MEG records | 2 hours | 
| Brain imaging | MRI and SPECT-CT records | 2 hours | 
| Electrical brain activity | EEG records | 2 hours | 
| Motor activity parameters | Motor platform records | 2 hours |
Anaerobic Exercises on Cardiac Workload, Peripheral Resistance and Lipid Index Among Grade 1 Hypertensive Young Adults

Study Overview
=================
Brief Summary
-----------------
Impact of resistance exercises on grade I hypertensive patients were monitored on three outcome measures that were blood pressure, peripheral resistance and lipid index after 12 weeks of intervention

Official Title
-----------------
Anaerobic Exercise Impact on Cardiac Workload, Peripheral Resistance and Lipid Index Among Grade 1 HTN Patients

Conditions
-----------------
Blood Pressure

Intervention / Treatment
-----------------
* Other: Exercise


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: grade I HTN Age 20-40years Both male and female Exclusion Criteria: unable to perform exercises Comorbidities like Diabetes

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Anaerobic exercise training<br> | Other: Exercise<br>* Resistance training using dumbbells and therabands<br>|
| Active Comparator: Aerobic exercise training<br> | Other: Exercise<br>* Resistance training using dumbbells and therabands<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Systolic blood pressure | Sphygmomanometer | From baseline to 12 weeks of training | 
| Peripheral Resistance | Ankle Brachial Index | From baseline to 12 weeks of training | 
| Lipid index | Hdl to ldl ratio blood test | From baseline to 12 weeks of intervention |
Safety and Efficacy of Long-term Somatropin Treatment in Children

Study Overview
=================
Brief Summary
-----------------
This study is conducted in Europe. The aim of this study is to evaluate safety during the long-term use of somatropin (Norditropin®) in children as well as efficacy on change in height. A subgroup of children small for their gestational age is included.

Official Title
-----------------
Non-interventional Study of the Safety and Efficacy of Long-term Somatropin Treatment in Children (GrowthWIN II / GrowthWIN II SGA)

Conditions
-----------------
Growth Hormone Disorder, Growth Hormone Deficiency in Children, Foetal Growth Problem, Small for Gestational Age, Genetic Disorder, Turner Syndrome, Growth Disorder, Idiopathic Short Stature

Intervention / Treatment
-----------------
* Drug: somatropin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: In need of somatropin or current user

Ages Eligible for Study
-----------------
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Users of somatropin<br> | Drug: somatropin<br>* Prescribed at the discretion of the treating physician according to product labelling<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of adverse events |  | Up to 10 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients continuing somatropin treatment |  | Up to 10 years | 
| Change in height |  | Up to 10 years | 
| Onset of puberty in children small for gestational age |  | Up to 10 years | 
| Co-morbidities in children small for gestational age |  | Up to 10 years |
New Methods to Diagnose Constrictive Pericarditis

Study Overview
=================
Brief Summary
-----------------
Until now, diagnosis of constriction was based on pressure changes of ventricle by conventional pressure-wide hemodynamic evaluation but not on ventricular volume change. This study will provide answers to persisting questions about volume changes during respiration in patients with constrictive pericarditis by directly measuring both right and left ventricular volume.

Official Title
-----------------
Pressure-Volume Analysis of Constrictive Pericarditis

Conditions
-----------------
Constrictive Pericarditis

Intervention / Treatment
-----------------
* Device: CD Leycom/Millar Instruments conductance catheter


Participation Criteria
=================
Eligibility Criteria
-----------------
Subjects referred for right and left heart catheterization will be eligible.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Pressure-volume relationship<br>Changes in pressure-volume relationships will be compared to changes in LV and RV systolic pressure during respiration. | Device: CD Leycom/Millar Instruments conductance catheter<br>* Conductance catheter-Pressure volume relationship<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Presence of constrictive pericarditis |  | 1 hour |
Effects of OMT on Premature Physiological Parameters

Study Overview
=================
Brief Summary
-----------------
Osteopathic manipulative treatment has been showed to reduce LOS in premature infants. Despite the clinical effectiveness, lack of data and information on the physiological underpinning effects during the treatment has been revealed. The aim of the study is to explore the immediate physiological effects of osteopathic treatment on premature infants

Official Title
-----------------
Effects of OMT on Premature Physiological Parameters: a RCT

Conditions
-----------------
Premature Infant, Physiological Stress

Intervention / Treatment
-----------------
* Other: osteopathic manipulative treatment
* Other: Sham


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: preterm infants Exclusion Criteria: congenital/genetic disease cardiovascular/neurological disease

Ages Eligible for Study
-----------------
Maximum Age: 2 Months

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: OMT<br> | Other: osteopathic manipulative treatment<br>* OMT will be used to treat premature infants after having performed a manual osteopathic assessment. Techniques used are indirect<br>|
| Placebo Comparator: Control<br> | Other: Sham<br>* the sham intervention consists in a stable skin-to-skin contact with the participant<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| heart rate | measure of heart rate | immediate | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| oxygen saturation | measure of oxygen | immediate |